NeuroBo Completes Enrollment for Phase 1 Trial of Promising Obesity Drug DA-1726

Enrolment in the single ascending dose (SAD) Part 1 of NeuroBo Pharmaceuticals, Inc.'s Phase 1 clinical study of DA-1726, a new dual oxyntomodulin analogue agonist intended to treat obesity, is now complete. Forty-five individuals have been recruited and randomly assigned to five cohorts, with DA-1726 to placebo ratios of six to three in each. According to Hyung Heon Kim, the company's president and CEO, the enrolment process' completion is a major accomplishment for NeuroBo and demonstrates the company's dedication to using differentiated medicines to improve cardiometabolic illnesses.

Pre-clinical research indicates that DA-1726 leads to better weight loss than semaglutide and that tirzepatide causes similar weight loss while requiring higher food consumption. Data from the 84th Scientific Sessions of the American Diabetes Association revealed that DA-1726 outperformed survodutide in terms of weight reduction and retention of relative lean body mass preservation. It also outperformed survodutide in terms of glucose lowering. Because of these features, NeuroBo thinks that DA-1726 has a higher tolerability profile than GLP-1 agonists that are presently on the market and those that are undergoing late-stage clinical studies, potentially making it a best-in-class medication for obesity.

The Phase 1 trial will examine the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeated ascending doses of DA-1726 in obese, otherwise healthy people. It will be a randomised, placebo-controlled, double-blind research. Part 2 is a MAD research that is presently recruiting people. It will involve about 36 individuals who will be randomised into four groups. The Phase 1 trial's main goal is to monitor adverse events, major adverse events, treatment-emergent adverse events, and adverse events (AEs) that result in treatment discontinuation in order to evaluate the safety and tolerability of DA-1726.